Accendra Health, Inc. announced on November 16, 2026, that it has received notice from the New York Stock Exchange (NYSE) Regulation that trading of its common stock has been suspended and proceedings to delist the stock have commenced. The NYSE determined that the company’s common stock is no longer suitable for listing based on abnormally low selling price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual.
The company does not intend to appeal the NYSE’s determination. As a result, Accendra Health’s common stock began trading on the OTCQB market under the ticker symbol “ACCH” on November 17, 2026. The company stated that this transition to the over-the-counter market will not affect its business operations or its reporting obligations with the U.S. Securities and Exchange Commission, nor will it conflict with any of its material debt or other agreements.
In a press release dated November 17, 2026, Kenny Gardner-Smith, President & Chief Executive Officer, stated that the company is focused on implementing decisive measures to support its turnaround and best position the company for long-term growth and success. The release also included forward-looking statements regarding the company’s future prospects and performance, including its expectations regarding the sale of its Products & Healthcare Services business and its ability to execute its value creation plan.